Genomtec (GMT) Q3 2024 earnings summary

Executive summary

• Focused on M&A activities and seeking strategic partners or technology sale to maximize shareholder value, with ongoing discussions and NDAs signed with major industry players, including NASDAQ-listed companies.

• Genomtec ID platform clinical trials in France and Poland continue, with flexibility to adjust trial pace to M&A needs; European Commission extended IVDR registration deadline to 2029.

• Oncology project (oncoSNAAT) advanced in single nucleotide change detection; next steps include sample volume optimization and genetic material isolation.

• Cash position remains secure, with over PLN 21.5 million in grant funding and share issue proceeds; grant funds expected to last until M&A transaction.

Financial highlights

• For 9M 2024: sales revenue negligible, grant income PLN 1,123k, R&D costs PLN 1,912k, general/admin/selling expenses PLN 8,496k.

• Operating result: -PLN 9,167k (vs. -PLN 6,819k in 9M 2023); net result: -PLN 9,326k (vs. -PLN 6,763k in 9M 2023).

• Cash and cash equivalents at period end: PLN 6,175k (would be PLN 10m if not for returned grant advance); equity: PLN 9,482k.

• Total assets: PLN 17,447k; long-term liabilities: PLN 4,476k; current liabilities: PLN 3,489k.

Outlook and guidance

• No material product sales expected until Genomtec ID commercialisation; current sales are one-off orders.

• Further funding for Genomtec ID development depends on successful grant settlements and investor contributions.

• Company does not publish financial forecasts.